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Abstract 
Background: Celiac disease (CD) is a chronic T-cell mediated inflammatory disorder 
of the small intestine. Overexpression of interleukin-15 (IL-15) and interferon-γ (IFN-
γ) is important components of the immunopathology in CD, but the function of these 
cytokines is not fully explored. Furthermore, retinoic acid (RA) has been shown to 
function as a co-adjuvant together with IL-15 to drive inflammatory immunity against 
dietary antigens. We have recently found that monocyte-derived CD14+CD11c+ cells 
are selectively increased in the active celiac lesion. Here we investigated the capacity 
of monocytes to activate gluten specific CD4+ T-cell clones (TCCs) in response to IL-
15 and IFN-γ, and explored the potential co-adjuvant effect of RA. 
Methods: Isolated CD14+ monocytes from human leukocyte antigen-DQ2+ (HLA-
DQ2+) individuals were pretreated with gluten and different combinations of IFN-γ, 
IL-15, transforming growth factor-β  (TGF-β) and RA, and subsequently incubated 
with gluten-specific intestinal-derived CD4+ TCCs to assess their stimulatory 
potential. Moreover, the monocyte responses to such pretreatment were characterized 
by T-cell proliferation assays, quantitative PCR (qPCR) and flow cytometry, and the 
T-cell cytokine production in response to pretreated monocytes was analyzed. 
Results: Pretreating CD14+ monocytes with IL-15 or IFN-γ significantly increased 
their capacity to induce the proliferation of gluten-specific TCCs, but no significant 
co-adjuvant effect of RA was detected. Although monocytes did not appear to respond 
directly to IL-15-stimulation, IL-15-treated CD14+ cells showed membrane bound 
expression of IL-15, indicating that IL-15 is trans-presented to the T-cells. 
Interestingly, IFN-γ was found to induce monocyte IL-15 expression at the 
transcriptional and protein level, and blocking IL-15 in the monocyte-T-cell co-
cultures significantly reduced T-cell proliferation. 
Conclusion: We have demonstrated that IL-15 and IFN-γ strongly enhance the 
capacity of CD14+ monocytes to activate gluten-specific CD4+ T cells; and the 
increased T-cell proliferation caused by IFN-γ stimulated monocytes was mostly 
augmented through IL-15. Our results suggest that intestinal CD14+ cells, by trans-
presentation of exogenous or endogenous IL-15 in response to proinflammatory 
factors, may play an important role in the activation of gluten-reactive CD4+ T cells in 
the celiac lesion.  
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1. Introduction 
1.1 General introduction 
1.1.1 Celiac disease 
CD is a common chronic inflammatory disorder of the small intestine, caused by an 
inappropriate immune response to dietary gluten proteins from wheat, barley and rye 
in genetically susceptible individuals, resulting in destruction of intestinal epithelium 
and remodeling of the intestinal mucosa. Gut lesions of most celiac disease patients 
completely normalize when gluten is excluded from the diet, but symptoms reappear 
after eating gluten again, thus indicating that gluten is the driving factor. CD occurs in 
children and adults with a prevalence of about one in 100 [1], and shows a strong 
HLA association. All patients are either HLA-DQ2 or HLA-DQ8, and patients, but 
not healthy subjects, have DQ2- or DQ8-restricted gluten-reactive CD4+ T cells in the 
intestinal mucosa. Although CD4+ T cells are important players in the disease 
process, T lymphocytes do not recognize protein antigens in its native form. 
Exogenous antigens, such as gluten, are first captured and processed by other immune 
cells, so-called antigen presenting cells (APCs), which then present processed 
antigens for the T cells [2]. Recent studies showed influx of monocytes in the small 
intestine lamina propria of treated CD patients following gluten challenge [3]. In fact, 
the increased recruitment of monocytes preceded the appearance of inflamed 
intestinal lesions, indicating that the monocytes participate in the initiation of the 
disease. However, knowledge of how the intestinal microenvironment affects the 
recruited monocytes is scarce. This study focused on the cytokines IL-15 and IFN-γ, 
both of which are highly upregulated in celiac lesion (1.3.5), and how they affect the 
capacity of monocytes as APCs  
 
1.1.2 Homeostasis in  the gut 
The human intestine constitutes the “inner body surface”, and this huge surface area, 
consisting of more than 100 m2 mucosa, is in direct contact with the outside 
environment. The intestinal mucosal surface is coated by a thick mucus layer, with a 
single layer of epithelial cells beneath, separating the body and its immune cells from 
the vast number of commensal bacteria (microbiota) in the gut. The intestinal organ 
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contain the highest number of leukocytes, thus, to maintain homeostatic conditions the 
activity of the intestinal immune system must be tightly regulated by several layers of 
control mechanisms. When maintaining immunological homeostasis we must tolerate 
the high antigen load of food proteins and the normal gut microbiota which is 
constantly present in the gut. Otherwise chronic intestinal inflammation would be the 
result. One important mechanism to maintain homeostatic condition is the mechanism 
of oral tolerance (1.2.5) which ensures that we do not react inappropriately to soluble 
proteins. 
Like all barrier tissues, the intestine contains an extensive mononuclear phagocyte-
network of bone marrow-derived APCs – so-called dendritic cells (DCs) and 
macrophages. DCs are cells of the immune system, which are specialized to 
differentiate between microenvironmental cues, like pathogenic or commensal 
bacteria and harmless antigens. After maturation, DCs migrate to draining lymph 
nodes, where they stimulate T cells in the context of peptide-MHC molecules. In 
response to this, naïve T cells have the capacity to differentiate into functionally 
distinct subsets of T helper cell type (Th) 1, 2, 17 and regulatory T cells (Tregs), 
depending on the signals received from DCs (Figure 1). Tregs are abundant and 
important for maintaining immune tolerance in the small intestine, whereas Th1, Th2 
and Th17 cells are essential for the elimination of intracellular bacteria and viruses, 
parasites, and extracellular bacteria and fungi, respectively. Mucosal DCs have a 
crucial role in generating and shaping immune response to a given stimuli; either by 
inducing Tregs and promoting immune tolerance under homeostatic conditions, or 
initiating a productive immune response against infectious agents – triggering Th1, 
Th2 or Th17 responses depending on the nature of the pathogen [4].  
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Figure 1: Priming naïve T‐cells. Mononuclear phagocytes samples antigen from the gut lumen, and dendritic cells 
(DCs) migrate to draining  lymph nodes. Dependent on the micro‐environmental stimuli, antigen  loaded CD103+ 
DCs shapes the T‐cell response by regulating differentiation of naïve T cells  into T regulatory cells, T helper cell 
type 1 (Th1), Th2 or Th17  cells. 
1.2 The mononuclear phagocytes system 
The mononuclear phagocyte system (MPS) is composed of monocytes, macrophages 
and DCs, and differentiation is determined at the stage of macrophage and DC 
progenitor (MDP) (Figure 2). MDPs are a subset of proliferating cells in the bone 
marrow that is devoid of lymphoid, erythroid and megakaryocytic potential, and can 
either differentiate into monocytes or common dendritic progenitors (CDPs). CDPs 
can further give rise to plasmacytoid dendritic cells (PDCs) or classical DCs (cDCs), 
and monocytes may differentiate into to macrophages or inflammatory DCs [5, 6].  
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Figure 2: Differentiation of monocytes, DCs and macrophages in mice. Hematopoietic stem cells (HSC) produce 
myeloid committed precursor (MP), giving rise to macrophage and DC precursor (MDP) which may further give 
rise to monocytes and common dendritic progenitors (CDPs). CDPs give rise to pre‐classical dendritic cells (pre‐
cDCs) or plasmacytoid dendritic cells  (PDCs), but have  lost  the ability  to differentiate  to monocytes  (Mo). Pre‐
cDCs are found in the blood, bone marrow and spleen. Pre‐cDCs may enter lymph nodes from the blood, where 
they  acquire  a mature  cDC phenotype  (CD8+ or CD8‐),  and  intestinal  lamina propria, where  they  give  rise  to 
CD11c+CD103+DCs. PDCs also migrate  from blood  to  lymphoid  tissue. MDP‐derived monocytes circulate  in  the 
blood, bone marrow and spleen giving rise to subsets of macrophages and DCs, but not to cDCs and PDCs. Under 
homeostatic  conditions monocytes  can  give  rise  to  alveolar macrophages,  or  lamina  propria  CX3CR1  antigen 
presenting cells. During inflammation monocytes may differentiate to inflammatory‐DCs and macrophages within 
the tissues[7] .  
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 1.2.1 Dendritic cells  
DCs are defined by their ability to prime naïve T-cells after migrating to draining 
lymph nodes [8, 9]. In the mouse intestine, two main populations of cDCs, derived 
from pre-cDCs, have been described: CD103+ CD11c+CD11b+ and CD103+ 
CD11c+CD11b- DCs [10]. Monocytes also have the potential to differentiate to DCs, 
which is well established for intestinal CX3CR1+ DCs and inflammatory DCs in the 
skin, gut and airways. However, at steady state only the subpopulation of CD103+ 
DCs emigrates from the lamina propria to the mesenteric lymph nodes, where they 
effectively present antigens to naïve T cells. Such cDCs are antigen-processing and 
presenting cells, with high phagocytic activity as immature cells, and high cytokine 
producing activity as mature cells. In addition, they are highly migratory and can 
migrate from tissue to lymphoid organs.  CX3CR1+ APCs are generally poor T-cell 
stimulators, and whether they should be defined as DCs or macrophages is 
controversial [7]. However, a recent study showed that in situations of intestinal 
bacterial dysbiosis, such cells may serve classical DC functions [11]. 
  
1.2.2 Monocytes 
Monocytes are found circulating in the blood, bone marrow and spleen, and may give 
rise to subsets of macrophages and inflammatory DCs after recruitment to tissues. 
Monocytes share many phenotypic functions with DCs, such as their ability to process 
and present antigen to T cells. They also possess phagocytic function, and the ability 
to produce inflammatory cytokines [7]. 
Monocytes were conventionally divided into two subpopulations: classical monocytes 
expressing HLA-DR+, CD14hi, CD11chi, CD11bhi and CX3CR1low, or CD16 
monocytes expressing HLA-DR+, CD14low, CD11c+, CD11b+, CD16hi and CX3CR1hi 
[12, 13]. More recently, monocyte nomenclature has been further subdivided into 
three subsets, segregating CD16 positive cells into two populations, based on CD14 
expression. thus the current nomenclature consists of CD14++CD16- classical, 
CD14++CD16+ intermediate, and CD14+CD16++ non-classical monocytes [14].
Another phenotypic monocyte marker is the chemokine receptor CCR2, which has 
been shown to be essential for the recruitment of mice classical monocytes, classified 
as CCR2+Ly6Chi [15], to inflamed tissues. In the tissues, Ly6C+ monocyte derived 
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cells express CCR7, and in mice with an inflamed gut such cells were found to be 
present in lymphatic vessels indicating that they are migratory. Thus it was suggested 
that monocytes can differentiate into migratory APCs capable of priming naïve T cells  
[16]. By analogy, CD14+CD11c+ monocytes were found to migrate into the small 
intestine celiac lesion, where they may further mature into potent APCs [3]. However, 
it has not been directly demonstrated that monocytes can differentiate into migratory 
DCs in humans. 
 
1.2.3 Macrophages 
Macrophages from various tissues, such as kuppfer cells, epidermal langerhans cells 
and microglia have been shown to be derived from the fetal yolk sac, and are 
maintained by local proliferation [17]. In contrast, the recruitment of monocytes into 
the small intestinal lamina propria appears crucial for maintaining distinct populations 
of differentiated tissue macrophages at this site, and these intestinal macrophages has 
been reported to be non-proliferative [18] [19]. In the steady state intestine of mice, 
LyC6high monocytes give rise to both inflammatory macrophages (CXCR1low/int) and 
resident macrophages (CXCR1high), in comparison with LyC6low monocytes which 
have little or no potential to replenish these macrophages in the non-inflamed 
intestine. Hence, LyC6high monocytes give rise to all macrophages, adopting a resident 
or pro-inflammatory phenotype dependent on the intestinal local environment [20].  
Direct evidence for monocyte origin of human intestinal macrophages is lacking. 
However, although early studies claim that intestinal macrophages are negative for 
CD14 [21-23], more recent studies indicate that the small intestine contains a 
population of CD14  CD11c  monocytes as well as mature macrophages expressing 
intermediate levels of CD14 [24, 25]
hi hi
. Tissue macrophages expressing CD14 is 
compatible with a model in where they are derived from recruited monocytes. 
 
1.2.4 Mounting an  appropriate immune response 
An appropriate immune response depends on the ability of effector and regulatory 
lymphocytes to migrate from lymph nodes to the site of infection or injury. 
In mouse models it has been shown that CD103+ DCs in the gut have the ability to 
induce the gut-homing receptors CCR9 and α4β7-integrin in responding T-cells, and 
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thereby induce lymphocyte migration to the intestine where antigen was originally 
encountered [26].  
The induction of T-cell gut-homing receptors depends on the capacity of gut DCs to 
synthesize RA through their expression of the retinal dehydrogenase (RALDH) 
enzymes. It has been shown in mice that CD103+ DCs express RALDH, and that the 
activity of RALDH appears to be dependent on RA derived from the intestinal 
epithelium or the bile [27].  
DCs express mRNA for Aldh1a2, the gene encoding RALDH2, and the expression of 
this gene is particularly high in the CD103+ intestinal DC subset. It has also been 
reported that induction of Treg development by CD103+ DCs is RA dependent. 
Generation of Tregs is important for induction of oral tolerance. Indeed, purified 
intestinal mouse CD103+ DCs have been shown to induce Tregs without the addition 
of exogenous factors. Blocking the action of TGF-β and RA abrogated their ability to 
induce Tregs, underlining the importance of RA and TGF-β as anti-inflammatory 
factors [27].  
 
1.2.5 Oral tolerance 
Pabst and Mowat [28] have proposed a multistep model of oral tolerance where 
antigen-loaded CD103+ DCs migrate from the small intestine to the mesenteric lymph 
nodes; in the mesenteric lymph node, RA produced by these DCs and local stromal 
cells induce expression of T-cell homing receptors, CCR9 and α4β7, and together 
with TGF-β promote differentiation of Foxp3+ regulatory T-cells (Tregs). Such Tregs 
then home back to the small intestinal lamina propria, where they undergo secondary 
expansion in response to IL-10 produced by tissue macrophages. Some of these Tregs 
may then exit the lamina propria via the lymph and promote systemic oral tolerance.  
In line with this, Coombes et al showed that the induction of tolerogenic T cells by 
CD103+ DCs require TGF-β and RA acting as a cofactor for inducing this regulatory 
phenotype. However, TGF-β can together with CD103+ DCs induce Foxp3 expression 
in naïve T-cells, where increasing amounts of TGF-beta correlate with a more 
abundant Treg polarization [29]. 
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1.2.6 In vivo  sources of RA and TGF­β 
Vitamin A is obtained from the diet either as all-trans-retinol, retinyl esters or β-
caroten. All-trans-retinol and β-caroten can then be oxidized to all-trans-retinal by 
ubiquitously expressed enzymes, like alcohol dehydrogenases or short chain 
dehydrogenase reductases. All-trans-retinal can then be further oxidized by RALDH 
to all-trans-retinoic acid [30]. Thus, generation of RA is RALDH dependent, and 
many cell types, including intestinal epithelial cells and gut-associated DCs express 
RALDH [31-33].  
There are several possible sources of TGF-β in the small intestine, one of them is 
CD103+ DCs, which express tgfb2, tissue plasminogen activator (TPA) and latent 
TGF-β binding protein 3 (ltbn3) mRNA, which are involved in secretion and 
activation of TGF-β [29], in addition TGF-β is expressed by the small intestinal 
epithelium in mice [34]. 
1.3 Celiac disease 
1.3.1 Pathophysiology of celiac disease 
CD is triggered by ingestion of gluten proteins, where gluten peptides crossing the 
epithelium into the lamina propria are deaminated by transglutaminase 2 (TG2) (see 
1.3.4), taken up by HLA-DQ2+ or HLA-DQ8+ APCs and presented to gluten specific 
CD4+ T-cells. Gluten-reactive T cells are primarily Th1 cells  [35], and their local 
production of IFN-γ may act directly on enterocytes, trigger amplified cytotoxicity of 
intraepithelial lymphocytes (IELs) against enterocytes, and block the function of 
Tregs. This leads to villous atrophy and crypt hyperplasia (Figure 3) [36] [37].  
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 Figure 3: Pathophysiology of celiac disease. Celiac disease is a T‐cell mediated inflammatory response to gluten 
peptides  in  the  small  intestine  lamina  propria with  an  increased  content  of  intraepithelial  lymphocytes  and 
lamina  propria  lymphocytes. Gluten  peptides  is  taken  up  in  the  small  intestine  lamina  propria  from  the  gut 
lumen,  and  deaminated  by  transglutaminase  2.  Deaminated  gluten  peptides  is  further  taken  up  by  antigen 
presenting cells (APCs), presented to gluten specific CD4+ T cells, inducing inflammation and a T helper cell type 1 
response [38]. 
 
1.3.2 HLA association in celiac disease 
Genome-wide association studies have demonstrated that CD is a polygenic disorder 
with involvement of many genes; the HLA locus is the most important genetic factor 
contributing to ~40% of the genetic variance of the disease. 
The general structure of HLA class II proteins is one α- and one β-chain, each 
consisting of two domains – a polymorphic α1- and β1- region and a highly conserved 
α2- and β2-region. The polymorphic α1- and β1- region form the antigen binding 
groove, and can bind various peptides of 14-25 amino acids, depending on the 
affinity[39]. Furthermore, these classical HLA class II molecules are expressed on the 
surface of APCs and there is almost a thousand different alleles, encoded by HLA-
DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA and HLA-DRB1[40]. The 
nomenclature for naming these genes begins with HLA and the gene name and up to 
four sets of digits separated by colons. The first set describes the allele group, and can 
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be determined by antibody recognition. The next set of digits describes the different 
subtypes, and represents different amino acid (aa) sequences of the encoded protein. 
The last two sets of digits describes any synonymous mutations in exons and introns, 
respectively [41]. 
Approximately 90% of celiac disease patients express HLA-DQ2.5, and the majority 
of the remaining CD patients express HLA-DQ8. HLA-DQ2.5 and HLA-DQ8 is 
encoded by DQA1*05:01/DQB1*02:01 and DQA1*03:01/DQB1*03:02, respectively 
[42]. The functional explanation of the strong association between HLA-DQ2.5 and 
HLA-DQ8 is their ability to bind and present modified gluten peptides to CD4+ T-
cells [43-45], and is well established that CD T-cell antigens preferentially bind to 
HLA-DQ2.5, as well as to HLA-DQ8 [46]. Interactions between negatively charged 
glutamate residues in deaminated gluten peptides preferentially interacts with anchor 
position p4, p6 and p7 in the HLA-DQ2.5 binding groove, or p1, p4 or p7 for HLA-
DQ8 [47, 48]. Thus, high affinity binding between the HLA-DQ2.5 and –DQ8 
molecule and modified gluten peptides help mediate the immunological synapse 
between APCs and CD4+ T-cells. The gluten peptides recognized by intestinal T cells 
are very rich in proline and glutamine residues, thus influencing immunogenicity of 
gluten. Proline  residues prevent breakdown of gluten peptides by digestive enzymes, 
and TG2 deaminates glutamine residues into glutamate residues with increased 
affinity to HLA-DQ2 and -DQ8 molecules (1.3.4) [38]. A 33-mer gluten peptide, 
capable of activating HLA-DQ2-restricted TCCs and gluten specific T-cell lines, has 
been found to be resistant against breakdown by all gastric, pancreatic and intestinal 
membrane proteases. Furthermore, this 33-mer contain high amounts of proline and 
glutamine residues, possessing the potential for reacting with TG2, additionally, 
homologs have been found in all food grains that are toxic for CD patients [49]. 
  
1.3.3 Non­HLA association factors  in  celiac disease 
There is also a strong genetic association outside the HLA locus, illustrated by 
concordance rates of approximately 75 % in monozygotic twins [50], and at least 39 
non-HLA CD risk loci are known [51]. Out of these known genetic risk loci, some of 
the genetic regions has been shown to play a role in regulating T cells (CD28 and IL-
2) and B-cells (ICOS and IL-21) in mesenteric lymph nodes, activation and 
differentiation of proinflammatory T cells (e.g., IL12A, TLR7/8, IRF4) and cell 
migration (e.g. chemokine receptors like CCR2) [50]. 
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1.3.4 Transglutaminase 2 in the context of celiac  disease 
TG2 is a 78-kilodalton (kDa), calcium dependent enzyme, with multifunctional 
biochemical properties, including the ability to post-translationally modify glutamine 
to negatively charged glutamate [52]. In CD pathogenesis, TG2 mediate its effect 
through deamination of gliadins, increasing the affinity of deaminated gliadin peptides 
for HLA-DQ2 and -DQ8, which can be recognized by gut derived T cells. TG2 is 
mainly expressed in the subepithelial region of the mucosa, and at higher levels in CD 
patients. Further, the effect of TG2 on pepsin-trypsin digested gliadin has been 
illustrated by performing T-cell proliferation assays with different APCs, resulting in 
increased  T-cell proliferation in response to TG2, independently of the specific APC 
type [53]. 
 
1.3.5 Intestinal  cytokine response in celiac disease patients  
The intestinal cytokine profile in CD patients was partly described by Nilsen et al in 
1998 [54]. All CD specimens expressed IFN-γ; in addition IL-2, IL-4, IL-5, IL-6 and 
TNF-α was detected in some specimens. Untreated celiac disease specimens 
expressed elevated levels of IFN-γ in comparison with normal controls, and in vitro 
gluten stimulation of treated CD specimens resulted in up-regulated IFN-γ expression. 
TGF-beta was also highly expressed, but expression levels was unchanged in treated 
or untreated CD specimens and non-CD specimens [54].  Additionally, IL-15 [55] and 
IL-17A [56, 57] has been reported to be over-expressed in lamina propria of patients 
with active CD. 
In the lamina propria of CD patients, there is an increase in the Th1 lymphocyte 
subpopulation, demonstrated by the upregulated expression of T-bet and IFN-γ in 
biopsies taken from untreated CD patients [35, 58].  
Nielsen et al [59] investigated the cytokine production of gluten specific T-cells 
(CD25+CD4+ TCCs) isolated from celiac lesions [60], and found that all the gluten 
specific TCCs analyzed secreted IFN-γ, in addition, some also secreted IL-4, IL-5 IL-
6, IL-10, TNF and TGF-β. These cytokines were shown to be up-regulated on a 
transcriptional level by semi-quantitative polymerase chain reaction (PCR) in four 
TCCs after pre-incubation with APCs and gluten peptides. However, only TGF-β was 
constitutively transcribed by the TCCs independent of gluten stimulation, although all 
four TCCs transcribed IL-10 and INF-γ after gluten stimulation. Additionally, some of 
the gluten specific TCCs contained mRNA for TNF-α, IL-2, IL-4, IL-5 and IL-6 [59]. 
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A more recent study showed that activated gluten specific TCCs secrete IFN-γ and IL-
21, but not IL-17 [61]. 
Another subpopulation which is increased in small intestine of active celiac disease 
patients are CD4+CD25+FOXP3+ T regulatory cells. These cells were shown to be 
present in the subepithelial layer of the lamina propria, and to be functionally 
suppressive [62] 
 
1.3.6  Increased  CD14+CD11c+   APCs  in   celiac  lesions   after  gluten 
challenge 
It was recently reported by Beitnes et al. that HLA-DQ+ APCs in healthy human 
duodenal mucosa can be divided into four subsets: CD163+ CD11c- macrophages, and 
CD11c+ DCs expressing either: CD163, CD103 or CD1c.  [63]. Consequent studies 
by Beitnes et al [3] showed that the number CD11c+CD14+ APC increased after 
gluten challenge in celiac lesions of CD patients, and that most of these cells were 
CCR2+. These findings indicate that the CD11c+CD14+ APC subpopulation originated 
from blood monocytes. In addition, they also showed that CD14+ monocytes from 
HLA-DQ2+ donors were capable of activating gluten specific T-cell proliferation upon 
pre-incubation with gluten peptides.  
 
 
1.3.7 Intraepithelial lymphocytes in the celiac lesion 
IELs of the small intestine represents a heterogeneous population consisting mainly of 
CD8+ memory-effector T-cells residing within the epithelial layer [64]. Early findings 
on the relative IEL cell count in non-CD controls and CD patients, on a gluten free or 
gluten-containing diet, showed increased levels in both groups compared to non-CD 
controls [65]. Subsequent studies has shown that IELs are important for CD 
immunopathology [66], and it has been proposed that the licensing of IELs to kill 
requires two factors; activated gluten specific CD4+ T cells, and a stressed epithelium 
expressing high levels of IL-15 and non-classical MHC class 1 molecules. Epithelial 
cells expressing these two factors can be targeted and destroyed by IELs in CD, 
showing the importance of IL-15 and non-classical MHC class 1 [2]. 
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In addition, IELs from untreated CD patients express IL-17A, IFN-γ and IL-10 [56, 
67] as well as FasL+, and has the ability to kill Fas+ enterocytes by Fas/FasL 
interaction [36]. 
1.4 Interleukin­15 and IL­15 receptor complex 
1.4.1 Identification  of IL­15 
Interleukin-15 was first discovered as a T-cell growth factor, purified from the 
monkey kidney cell line CV-1/EBNA. Based on the N-terminal sequence data, cDNA 
encoding the cytokine was isolated and expressed in mammalian cells, and the 14-15 
kDa glycoprotein was designated IL-15 [68, 69]. Due to the similarities between IL-2 
and IL-15 in receptor binding and functional responses, the possibility that IL-15 
utilizes components of the IL-2 receptor (IL-2R) complex was investigated by Giri et 
al [69]. They revealed that IL-2R-β and the common γ subunits are required for IL-15 
binding and signaling, but the third component of the IL-2R, the IL-2Rα subunit, was 
not needed for binding or signaling of IL-15. In addition, IL-15 receptor (IL-15R) 
were found to be expressed by a range of different cells types, including 
lipopolysaccharide-stimulated monocytes, PHA-stimulated PBMCs, vascular 
endothelial cells, NK cells and T-cells [69]. 
 
1.4.2 Cellular sources of IL­15  
In patients with active celiac disease, IL-15 is massively up-regulated in the small 
intestine lamina propria, and can also be detected in intestinal epithelial cells [55]. 
Doherty et al [70] showed that IL-15 mRNA can be isolated from several sites, 
including spleen, liver and lung, in addition, macrophages were found to be a major 
source of IL-15 in mouse lymphoid tissues. Human blood-derived DCs has also been 
shown to produce functionally active IL-15 following stimulation [71], and 
monocytes up-regulate IL-15 expression upon IFN-γ stimulation [72]. 
 
1.4.3 Short and long isoforms of IL­15 
There are two IL-15 splice variants, differing in the signaling region, and are 
designated long signal peptide (LSP) and short signal peptide (SSP) IL-15. The LSP 
consist of 48 amino acids (aa) and the SSP consist of 21-aa, with only 11 aa residues 
shared between these signal peptides. The SSP-IL-15 isoform is mostly located in the 
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cytoplasm and nucleus, in contrast to the LSP-IL-15 isoform that has been observed in 
the ER, and thus is considered secretable. Supernatant of COS cells transfected with 
LSP-IL-15 or SSP-IL-15 expression constructs, where tested with a biological assay 
using IL-2 dependent CTLL-2 cells. These IL-2 dependent cells did not proliferate in 
the presence of supernatants from SSP-IL-15 transfected COS cells, whereas CTLL-2 
cells subjected to supernatant from LSP-IL-15 responded by proliferating [73]. Since 
LSP-IL-15 is the only secretable isoform, it’s assumed that SSP-IL-15 do not affect 
adjacent target cells. However, Bergamaschi et al [74] presented evidence that SSP-
IL-15 actually can be secreted and bioactive as long as IL-15Rα is co-expressed.  
 
1.4.4 IL­15 Receptor  complex 
The biological activity of IL-15 is similar to IL-2 in its ability to stimulate 
proliferation of the T-cell line CTLL.2, and PHA stimulated PBMCs. It thus follows 
that IL-15 utilize components of the IL-2R complex, as demonstrated by Giri et al in 
1994 [69]. In fact, they showed that IL-15 is both dependent on IL-2Rβ and the 
common-γ chain, and in addition suggested that IL-15 can induce dimerization of 
soluble β and γ IL-2R subunits. Furthermore, it was demonstrated that the functional 
IL-2R complex is not sufficient for IL-15 binding, and that IL-2R α is not involved in 
the binding of IL-15. 
Since IL-2Rβ and the common-γ chain is not sufficient for IL-15 signaling alone, 
there had to be another component involved in binding IL-15. This component is 
structurally related to IL-2R α-chain, and is known as IL-15R α-chain [75].  
The components of the IL-15R complex have different affinities for IL-15 dependent 
on how they are combined, hence, an intermediate (Ka≈10-9 M)  affinity for the IL-
15R β-/γ-chain complex [76] and high affinity (Ka≥10-11M)  for the IL-15R α-chain 
[75]. It has also been shown that soluble IL-15/IL-15Rα complex have an increased 
affinity for IL-15R β-chain compared to soluble IL-15 alone [77]. However, when 
investigating dynamics of IL-15 and IL-15Rα binding, it was demonstrated that IL-15 
can be trans-presented (Figure 4) and undergo an IL-15Rα mediated recycling 
process. In line with this, cells transfected with IL-15 and IL-15Rα secrete low 
amounts of IL-15 relative to cells transfected with IL-15 alone, and biological active 
IL-15/IL-15Rα complexes has been detected on the plasma membrane of IL-15 
producing cells [78]. 
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Figure 4: IL‐15 trans‐presentation. IL‐15 can be trans‐presented by IL‐15Rα expressing cells to cells expressing IL‐
15Rβ  and  common  gamma  chain.  IL‐15  is  co‐expressed  with  IL‐15Rα  and  presented  to  a  neighboring  cell 
expressing IL‐15 Rβ/γ complex, this results in phosphorylation of jak1 and jak3 [79]. 
 
1.4.5 IL­15 signaling 
IL-15 binds to the IL-15R complex and signals through the IL-15Rβ chain and 
common γ chain [69] by inducing tyrosine phosphorylation of both JAK1 and JAK3. 
Cytokines which activate JAKs also activate tyrosine phosphorylation of transcription 
factors known as Signal Transducer and Activator of Transcription (STAT), and the 
STATs shown to be phosphorylated upon IL-15 signaling are STAT3 and STAT5 
[80].  
1.5 Co­adjuvant effect of RA and IL­15 
A possible association between RA (isotretinoin), used to treat acne, and 
inflammatory bowel disease has been reported [81]. This finding is compatible with 
recent mice studies, which showed that RA has a co-adjuvant effect together with IL-
15, affecting T-cell differentiation and activation. In the presence of IL-15, RA acted 
as an adjuvant to promote inflammatory Th1 and Th17 responses, preventing Treg 
induction. This effect was mediated through DCs, responding to RA and IL-15 by 
inducing phosphorylation of JNK, thus producing IL-12p70 and IL-23. [82]. 
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2. Project description 
CD is a T-cell mediated inflammatory response to gluten in the small intestine 
mediated by APCs [83]. Based on a recent study by Beitnes et al [3], where they 
showed an increase of CD14+CD11c+ APC in small intestine lamina propria after 
challenging celiac disease patients with gluten, it is suggested that newly recruited 
blood monocytes are involved in the immunopathology of CD by presenting gluten 
peptides to gluten-specific T cells in the lamina propria. In active CD, IFN-γ and IL-
15 is up-regulated in small intestine lamina propria [55]. Moreover, IFN-γ stimulated 
monocytes have been shown to up-regulate IL-15 expression [72], and RA together 
with IL-15 has been shown to have a co-adjuvant effect on immune responses to 
dietary antigens [82]. Based on this information the aims of this study were as 
follows: 
 
1. Assess whether IL-15 and IFN-γ affect HLA-DQ 2+ monocytes ability to 
activate gluten specific T-cell proliferation 
2. Assess whether RA functions as an adjuvant together with IL-15 in the 
activation of monocytes 
3. Investigate by which mechanisms monocytes respond to these cytokines 
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3 Materials and Methods 
3.1 Materials 
All reagents were from Sigma-Aldrich unless otherwise noted. The suppliers of 
antibodies and primers used in the present study are listed in table 1 and table 2. 
 
3.1.1 Biological  material  
The cells used in this study were CD4+ gluten specific TCCs, CD14+ blood 
monocytes from HLA-DQ 2+/- donors and peripheral blood mononuclear cells 
(PBMCs). The gluten specific TCCs were provided by the research group headed by 
Professor Ludvig Sollid (Center of Immune regulation, Oslo, Norway). Monocytes 
and PBMCs were isolated from buffy coats, ordered from Oslo blood bank (Oslo 
University Hospital). 
 
3.1.2 Culturing reagents  
Cell culturing reagents used in this study were BioWhittaker RPMI 1640 without L-
glutamine (Lonza), L-glutamine (Lonza), Pen strep (Lonza), fetal calf serum (FCS) , 
human serum (HS) (IMMI), recombinant human TGF-β1 (rhTGF-β1) (R&D 
Systems), rhIL-15 (R&D Systems), all trans-Retinoic Acid, LF-33 (p1502.4, gliadin) 
(GL Biochem (Shanghei)), rhIFN-γ (R&D Systems), 3H thymidine 
(HartmannAnalytic) and Brefaldin-A. To expand TCCs, Dynabeads CD3/CD28 T-
Cell Expander (Invitrogen), IL-2 (PeproTech), IL-15 (R&D Systems), PHA and β-
mercaptanol was used. 
 
3.1.3 Isolating and freezing cells  
Reagents used to isolate cells were lymphoprep (Axis-shield), Dynabeads® 
Untouched™ Human Monocytes (Invitrogen) and CD14 MicroBeads 
(Miltenyibiotec).  
Reagents used for freezing down cells were dimethyl sulfoxide (DMSO) (Merck), and 
FCS. 
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3.1.4 Antibodies  
The antibodies used in this study are listed in the table below (table 1) 
Antigen Conjugated Host Dilution Source Method 
hCD14 APC-Cy7 Mouse 5:100 Biolegend Flow cytometry 
hCD11c FITC Mouse 10:100 Biolegend Flow cytometry 
hIL-15 APC Mouse 10:100 R&D Systems Flow cytometry 
hIL-15  Mouse 0.2µg/mL R&D Systems Neutralization 
Isotype for neutralizing 
hIL-15 ab 
 Mouse 0.2µg/mL Sigma-
Aldrich 
Neutralization 
hCD19 PacB Mouse 10:100 Biolegend Flow cytometry 
hHLA-DQ2 FITC Mouse 1:250 IMMI Flow cytometry 
Isotype-hHLA-DQ2 FITC Mouse 20:100 BD bioscience Flow cytometry 
hpSTAT5  Rabbit 1:100 CellSignaling  Flow cytometry 
hpSTAT6  Rabbit 1:100 CellSignaling  Flow cytometry 
Anti-rabbit PE Goat 1:500 Southern 
biotechnology 
Flow cytometry 
IL-2 Pecy7 Rat 5:100 Biolegend Flow cytometry 
IL-17A pe Mouse 5:100 Biolegend Flow cytometry 
IFN-γ A488 Mouse 5:100 Biolegend Flow cytometry 
CD3 APC Mouse 10:100 BD bioscience Flow cytometry 
FITC:   Fluorescein isothiocyanate, APC: Allophycocyanin, PE: phycoerythrin, PE-Cy7: phycoerythrin- cyanine7 APC-Cy7: 
Allophycocyanin -cyanine7, PacB: pacific blue 
 
3.1.5 Flow  cytometry reagents  
Flow cytometry reagents used in this study were Fixable Viability Dye eFluor 450 
(eBioscience), paraformaldehyde and methanol (Merck). Staining buffer used to wash 
and stain cell suspensions contained PBS supplemented with 10% FCS and 0.1% Na 
azid. For compensation, PBMCs or oneComp eBeads (eBioscience) were stained with 
fluorochrome conjugated antibodies. 
 
3.1.6 Storing and isolating RNA 
The reagents used in this study to isolate RNA were Glycogen (Ambion), TRI reagent 
(Ambion), Ethanol, isoproanol (Fluka Analytical), 1-Bromo-3-Chloropropane (BCP), 
RNeasy mini kit (Qiagen). 
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3.1.7 PCR 
The primers used in this study for PCR are listed in the table below (table 2) 
Table 2 Primers 
Description Sequence Concentration Source 
hLSP IL-15.for TTGGGCTGTTTCAGTGCAGGG 100 nM Invitrogen 
hLSP IL-15.rev GTTCCTCACATTCTTTGCATCCAG 100 nM Invitrogen 
hSSP IL-15.for TGGCCCAAAGCACCTAACCT 100 nM Invitrogen 
hSSP IL-15.rev GTTCCTCACATTCTTTGCATCCAG 100 nM Invitrogen 
hHRPT. For AATACAAAGCCTAAGATGAGAGTTCAAGTTGAGTT 100 nM Invitrogen 
hHRPT. Rev TTAGGAATGCAGCAACTGACATTTCTAAAGTAC 100 nM Invitrogen 
hHRPT. Rev CTATAGGCTCATAGTGCAAATAAACAGTTTAGGAAT 100 nM Invitrogen 
Oligo dT CTGAATTCTTTTTTTTTTTTTTT 20pmol/µl Invitrogen 
hLSP-IL-15: human long signaling peptide interleukin 15, hSSP-IL-15: human short signaling peptide interleukin 15, hHRPT: 
human hypoxantine phsophoribosyltransferase. 
.
3.1.7.1 Reverse transcriptase PCR 
Reagents used for reverse transcriptase PCR (RT-PCR) was SuperScriptTM III RT 
(Invitrogen), DTT (Invitrogen), First strand buffer (Invitrogen), deoxyribonucleotide 
triphosphate (dNTP) (GE Healthcare (illustra)), Rnasin (Promega) and 
Diethylpyrocarbonate (DEPC) water. 
 
3.1.7.2 Real time PCR 
Reagents used for Real time PCR were dNTP (GE Healthcare (illustra)), HotStarTaq 
DNA Polymerase (QIAGEN), PCR Buffer (QIAGEN), MgCl2 (QIAGEN), EVA 
Green (BIOTIUM). 
 
3.1.7.3 Gel electrophoresis 
The agargel was made from LE agarose (SeaKem), ethidium bromide and 1x TBE 
buffer. Reagents used to run samples were 6x Xylene Cyanole gel loading buffer 
(Bio‐Rad), 100 bp DNA  ladder (New England Biolabs) and 1x Tris/Borate/EDTA 
(TBE) buffer. 
 
 
31
3.2 Methods 
3.2.1 Cell  culture and treatment  
Monocytes were cultured in RPMI medium supplemented with 1% L-glutamine, 1% 
P/S and 1 or 10% FCS. Monocytes, to be used in different experimental setups, was 
pre-treated with combinations of 1.7 µM gliadin peptide, 100 mM RA, 40ng/mL 
TGF-β, 250 ng/mL IL-15, and 100 U/mL IFN-γ. 
Monocytes-T-cell co-cultures were cultivated in RPMI medium supplemented with 
1% L-glutamine, 1% P/S and 10% HS.  
During T-cell expansion, cells were cultured in RPMI medium supplemented with 1% 
L-glutamine, 1% P/S, 0.0007 % 2β-mercaptoethanol and 10% HS. 
All cell cultures were incubated at 37 degree Celsius in a humidified 5% CO2, 95% air 
incubator, and all cell culturing work were performed in sterile hoods to prevent cell 
culture infections. 
 
3.2.1.1 Proliferation assay 
Monocytes from HLA-DQ 2+ donors were pretreated with or without 1.7 µM gliadin 
and combinations of 250 ng/mL IL-15, 100 U/mL IFN-γ, 100 nM RA, 40 ng/mL and 
TGF-β over night. The next day monocyte cultures were washed 3 times with PBS 
and then co-cultured with gluten specific TCCs for 4 days, adding 20 µL 3H 
thymidine solution (0.05 mCi/mL) per 150 µL medium one day before harvesting the 
cell cultures. At day 5, cell cultures were harvested on a Harvester 96 (Tomtec) and 
then measured using MicroBeta plate counter (PerkinElmer).  
 
3.2.1.2 Analyzing STAT phosporylation 
Cells were equilibrated in complete 10% FCS RPMI medium at 37 degrees for 
approximately 1 hour before activation with 250 ng IL-15 or 20 ng/mL IL-2 in 200 
µL for 15 minutes, followed by fixation with 1 mL 1% PFA and incubating at room 
temperature for 10 minutes. Cells were then washed before resuspending in cold 
methanol and incubated at 4 degrees for 10 minutes. For primary antibody staining, 
cells were washed with staining buffer and then resuspend in staining buffer 
containing desired primary antibodies (table 1), and incubated for 15 min in the dark 
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at 4 degrees for 15 min. For the secondary staining, cells were washed, resuspend in 
staining buffer containing desired secondary antibody (table 1), and incubate for 15 
min in the dark at 4 degree Celsius for 15 min. Finally, cells were washed, 
resuspended in staining buffer and analyzed as described in section (3.2.4). 
 
3.2.1.3 Freezing and thawing cells 
Cell samples were resuspended in medium containing 90% FCS and 10% DMSO, 
aliquoted  into cryotube vials (Thermo scientific) and frozen at -80 degree C in 
Nalgene cryo containers (Thermo scientific) before storing in N2(l). 
Cells were thawed in a 37 degree water bath until there was almost no ice left in the 
cryotube vial, and then transferred to new 15 mL falcon tubes containing 
approximately 8 mL preheated 20% FCS RPMI medium. Following this, tubes 
containing cell suspensions were centrifuged at 300 g for 5 minutes before 
resuspending in the desired medium. 
 
3.2.1.4 Viability assay of fresh versus frozen monocytes 
Monocytes, freshly isolated or frozen and thawed, were cultured overnight in 
complete 1% FCS RPMI medium, harvested and stained with hCD14 specific 
antibody (table 1), as described in section (3.2.4.1). The viability of freshly isolated 
versus frozen monocytes was quite similar (data not shown). 
 
3.2.1.5 Proliferative ability of gluten specific T­cells 
CD4+ tissue derived gluten specific TCCs were provided by the Sollid group. The 
proliferative ability of different TCCs (TCC: 430.1.142, 493.3.4.33, 412.5.28 and 
TCC: 436.5.3) was tested in a standard proliferation assay as described in section 
(3.2.1.1).  
T-cell response to IL-15 and the neutralizing effect of anti-hIL-15 antibody used 
during the blocking assay (3.2.1.8) was tested by culturing TCCs (TCC: 378.3.36, 
378.3.78) with/or without 0.2 µg/mL anti-IL-15 blocking antibody or an isotype 
control (table 1) and 100, 30, 10 or 3 ng/mL IL-15 at day 0. 20 µL 3H thymidine 
solution (0.05 mCi/ml) per 150 µL medium was added at day 2, before harvesting on a 
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Harvester 96 and then measuring thymidin incorporation using MicroBeta plate 
counter at day 3 (data  not shown). 
 
3.2.1.6 T­cell response to gliadin antigens 
Gliadin peptide, p1502.4, to be used in future experiments, was compared with one 
old batch of the same protein and gliadin CTTG (Institute of Immunology, IMMI, 
Rikshospitalet University Hospital and University of Oslo). HLA-DQ2+ monocytes 
and Epstein Barr Virus-immortalized B-cells (IMMI) were used as antigen presenting 
cells. APCs were pre-treated overnight with or without peptides and IL-15 before 
adding gluten specific TCCs. Remaining procedures was performed as described in 
section (3.2.1.1). APCs incubated with gliadin p1502.4 induced T-cell proliferation 
equally good as the old batch (data not shown). 
 
3.2.1.7 T­cell monocyte ratio 
Optimal T-cell monocyte ratio was established by cultivating 100 000, 20 000 or 
5 000 monocytes, pretreated with/without 250 ng/mL IL-15 and 1.7 mM gliadin 
peptide, further cultured, harvested and analyzed as described in section (3.2.1.1).  
 
3.2.1.8 Blocking assay 
Blocking assays was used to investigate the involvement of IL-15 in co-cultures with 
monocytes and TCC cells. 0.2µg/mL of anti hIL-15 blocking antibody or an isotype 
control (table 1) were added to the monocyte cultures, pretreated overnight with 250 
ng/mL IL-15 or 100 U/mL IFN-γ, washed with PBS, and incubated for 15 min at 37 
degree C before adding gluten specific TCCs. These co-cultures were then further 
cultivated, harvested and analyzed as described in section (3.2.1.1). 
 
3.2.1.9 Expanding T­cell clones 
PBMCs from two donors, isolated as described in section (3.2.5.1), were washed 
twice with PBS, irradiated with 50 gy, centrifuged at 300 G and resuspend in 10 % 
HS. Two vials of TCC (8 million T-cells) were then thawed, centrifuged at 300 G and 
resuspend in the solution with irradiated PBMCs. To this solution, 1 µg/mL PHA, 10 
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U/mL IL-2 and 1 ng/mL IL-15  was added before transferring to a 24 well plate, 0.5-
0.7 million cells in 1.3 mL per well. Medium containing 10 U/mL IL-2 and 1 ng/mL 
IL-15 were later used to split cell cultures after three or four days. At day five, 
medium containing no cytokines was used to split cell cultures. Finally, cells were 
harvested, counted and frozen down at day 7 as described in section (3.2.1.3). 
 
3.2.2 RNA isolation and Polymerase Chain Reaction  
In order to analyze regulation of gene transcription, RNA was isolated and used to 
synthesizing complementary DNA (cDNA) by reverse transcriptase PCR, which was 
subsequently used for qPCR. 
 
3.2.2.1 Lysing and storing cell suspension for RT­PCR 
Cell suspensions were centrifuged for 5 minutes at 300 G, resuspended in 500 mL of 
TRI Reagent, incubated at room temperature for 5 minutes and then frozen at -80 C. 
At later time points, samples were thawed and RNA was isolated. 
 
3.2.2.2 Isolating RNA 
Frozen TRI reagent solutions, containing lysed cells, were thawed at room 
temperature, consequently adding 50 µL BCP per 500 µL, incubated at room 
temperature for 5-15 minutes before centrifuging at 12000 g for 15 minutes at 4 
degree C. From this point, RNA was isolated by following Applied Biosystems TRI 
Reagent solution RNA isolation reagent protocol (Invitrogen) or Qiagen RNesay mini 
kit. When using Qiagen RNesay mini kit, the clear phase from the TRI reagent/BCP 
solution was transferred to new tubes and mixed with one volume of 70% ethanol. For 
the Applied Biosystem RNA isolation protocol (Invitrogen), 1 µL glycogen was 
added together with isopropanol to visualize the RNA. RNA concentration was 
measured on a NanoDrop spectrophotometer ND-1000 (Nanodrop Technologies). 
 
3.2.2.3 Reverse transcriptase PCR 
RT-PCR was used to synthesize cDNA, which was further used for qPCR. Each 
reaction contained RNA (1 µgram or less), 1 µl oligodT (table 2), 0.5 µl 200 U/µl 
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SuperScriptTM III RT, 2 µl 0.1 M DTT, 4 µl 5x first strand buffer, 1 µl 100 µmol 
dNTP, 0.5 µl 40 U/µl Rnasin and DEPC water giving a total volume of 20 µl. 
The RT-PCR consisted of one cycle; 50 degree C for 60 minutes, and 70 degree C for 
15 minutes. 
 
3.2.2.4 Real­time PCR 
QPCR was used to quantitatively measure the relative amount of RNA transcripts 
from different cell populations. For all the qPCR experiments, a Stratagene Mx3005P 
(Agilent Technologies) was used, and each reaction consisted of 0.5 µl 100 µmol 
dNTP, 0.125 µl 5000 U/ml HotStarTaq DNA Polymerase, 2.531 µl 10x PCR Buffer 
supplemented with 1.25 % BSA (QIAGEN), 25mM MgCl2 (amount dependent on 
primer set used), 0.625 µl 20x EVA Green, 5 µl cDNA (10 X diluted cDNA solution, 
added at separate bench) and ddH2O to reach a total reaction volume of 25 µl per 
sample. All samples were run in triplicates, and the optimal MgCl2 concentration per 
primer set was titrated from 1.5 mM to 4.0 mM. 
The qPCR consisted of up to 40 cycles; 95 C for 30 s, 60 C for 30 s, finishing each 
cycle with 72 C for 30 s and measuring absorbance. Finally each qPCR ended with a 
melting curve analysis consisting of one cycle; 95 degree C for 60 s, 57 degree C for 
30 s, finishing off with a temperature rise up to 95 degree C while measuring melting 
points.  
The threshold is the basis for all Ct (threshold cycle) values and should therefore be 
the same across all PCR array runs in one analysis, this threshold value was set 
according to RT2 ProfilerTM PCR Array System (SABiosciencesTM). To further 
analyze the relative transcription levels, Ct values were exported and analyzed by the 
ΔΔVt method according to toRT2 ProfilerTM PCR Array System (SABiosciencesTM). 
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3.2.3 Gel electrophoresis 
Gel  electrophoresis was  used  to  establish  the  optimal MgCl2  concentration  for 
PCR, and product quality per primer set. The agarose gel was made by heating 1 
x TBE buffer containing 2% agar in the microwave until boiling, twice, allowing 
the agar to dissolve properly. 0.5 ng/mL ethidium bromide was added to the agar 
solution, when  temperature was approximately 50 degree C,  and  consequently 
poured into a casting tray, with a comb inserted. After the gel cooled down, the 
comb  was  removed  and  the  casting  tray  was  placed  in  an  electrophoresis 
chamber  filled  with  1x  TBE  buffer.  Then  PCR  product,  mixed  with  6x  xc  gel 
loading buffer, and 100 bp DNA ladder was loaded to the desired wells. To finally 
separate PCR products and visualizing them, the gel was run for approximately 1 
hour at 80 V and visualized by UV‐light using a gel Doc (Bio‐Rad). 
 
3.2.4 Flow  cytometry 
Flow cytometry was used to measure the presence of fluorescently labeled antibodies. 
All compensations for surface and intracellular staining were done by using oneComp 
eBeads, or PBMCs stained with desired antibodies. Standard staining buffer (3.1.5) 
was used during all procedures unless otherwise noted. All samples were run on a 3-
laser LSR II (BD), and compensations were either done in FACSdiva (BD) or flowjo 
(Tree Star Inc), and the final analyzing was done in flowjo. 
 
3.2.4.1 Surface staining with antigen specific antibodies 
To investigate different cell markers and cell functions, surface staining was 
performed; antibodies used for this procedure are listed in table 1. Cell suspensions 
were first washed, before re-suspending in buffer containing desired antibodies. These 
antibodies are fluorochrome conjugated and will fade if exposed to light, thus 
following this point it is important to keep cell suspensions on ice and in the dark. 
Antibody stained samples were incubated for 15 min before washing, and 
resuspended in buffer. 10 µL 5 µg/mL propidium iodine solution was added to each 
sample right before analyzing by flow cytometry.  
 
3.2.4.2 Intracellular staining with antigen specific antibodies 
All intracellular staining was done according to the standard protocol from BD (BD 
Cytofix/cytoperm plus Fixation/Permalization Kit) using antibodies listed in table 1. 
Live/dead staining was performed, using Fixable Viability Dye Cell Staining 
following standard protocol (eBioscienceTM), before surface and intracellular staining. 
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3.2.5 Isolating cells  
3.2.5.1 Lymphoprep 
Lymphoprep was used to isolate PBMCs from full blood or buffy coat. One buffy coat 
was first diluted to a total volume of 200 mL with PBS, before aliquoting it in six 50 
mL falcon tubes already containing 10 mL lymphoprep each. These tubes were then 
centrifuged at 800g for 20 minutes. After this, the white phase containing PBMCs 
were transferred to new tubes, before washing twice with PBS, and resuspending in 
desired medium. 
 
3.2.5.2 Dynabeads 
Dynabeads were used to isolate cells from PBMC solutions, by negative selection. 
Most of the CD14+ monocytes (with an exception of donor 16) were isolated from 
buffy coats according to the Dynabeads CD14+ untouched negative isolation kit 
standard protocol (Invitrogen). 
 
3.2.5.3 MACS beads 
MACS beads were used to isolate cells from PBMC solutions (only donor 16), 
according to MACS CD14+ positive isolation kit standard protocol (Miltenyibiotec). 
 
3.2.6 Statistical analysis  
All statistical analysis was done in GraphPad Prism 5, using paired t-test. 
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4 Results 
4.1 Screening for HLA­DQ 2+ blood donors 
Screening blood donors for the HLA-DQ 2 phenotype was done to obtain monocytes 
with the ability to present gluten to gluten specific T-cells. Peripheral blood 
monocytes does not express surface bound HLA-DQ molecules, so to be able to 
screen for HLA-DQ 2+ patients, CD19+ B-cells were stained and analyzed for the 
presence of HLA-DQ 2. 
 
Figure  1: HLA‐DQ  2  screening.  Peripheral  blood mononuclear  cells  (PBMCs)  isolated  from  a  buffy  coat were 
stained with CD19‐ and HLA‐DQ 2/isotype control antibodies, and analyzed by flow cytometry, as displayed: (A) 
Isotype control, (B) HLA‐DQ‐ donor and (C) HLA‐DQ+ donor. Propidium iodide ‐ exclusion was used to detect live 
cells. 
 
Figure 1 shows both a HLA-DQ 2 positive and negative donor, including an isotype 
control. CD14+ monocytes from HLA-DQ 2 positive blood donors were further 
isolated by negative selection, with a typical purity of >90%, and further used in co-
cultures with gluten-specific TCC cells. 
 
 
39
4.2 IL­15 stimulation significantly enhance monocyte activation of 
tissue derived CD4+ gluten­specific TCC cells 
To investigate whether monocytes pre-treated with IL-15 more efficiently activated T-
cell proliferation, monocytes were cultured overnight with or without IL-15 and 
gluten, and further co-cultured with gluten specific TCC cells for 4 days, adding 3H 
thymidine approximately 20 hours before harvesting and measuring thymidine 
incorporation. 
 
Figure 2: IL‐15 pre‐treatment augmented T‐cell proliferation. Monocytes cultured overnight with or without IL‐
15  and  gluten,  and  further  co‐cultured  with  gluten  specific  T‐cell  clones  for  4  days,  adding  3H  thymidine 
approximately 20 hours before harvesting and measuring thymidine incorporation, as depicted. A) Activation of 
gluten specific T‐cell clones by monocytes from HLA‐DQ 2+ donors, 21 experiments, 10 monocytes donors and 4 
T‐cell clones. B) Control experiment with HLA‐DQ 2 negative donor revealed no T‐cell proliferation, n=1. Statistics 
were done using paired t test. ***≤0.005 
 
Monocytes pre-treated with IL-15 significantly enhance gluten dependant T-cell 
proliferation relative to monocytes cultured in absence of this cytokine. This was 
repeatedly shown using a large number of individual monocyte donors and several 
different gluten specific TCCs (Figure 2A). Cultures without gluten (Figure 2A) 
resulted in low levels of T-cell proliferation, showing that the TCC cells are 
dependent on gluten to proliferate in this system. Further, the proliferation was 
dependent on HLA-DQ 2 as the proliferation assay using monocytes from HLA-DQ 
2- donor abrogated the proliferation (Figure 2B). 
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4.3 Monocytes can display surface bound IL­15 
The increased proliferation could be the result of trans-presentation of IL-15 by 
monocytes, so we assessed the binding capacity of IL-15 on monocytes by pre-
treating monocytes with IL-15 over night, and subsequently staining with 
fluorochrome conjugated antibodies specific for IL-15 before analyzing by flow 
cytometry. 
 
 
Figure 3: Monocytes are capable of binding IL‐15. Monocytes were pre‐treated over night with/without IL‐15 as 
depicted, stained for surface bound  IL‐15 and analyzed using flow cytometry. A) Representative flow plot from 
one monocyte donor pre‐treated with  (red) or without  (blue)  IL‐15. B) Percentage of  IL‐15 positive monocytes, 
treated as depicted. Gating was performed according to CD11c, and Propidium  iodide was used to discriminate 
dead cells. N=5 
 
Results in figure 3A and B shows that monocytes have binding potential for IL-15, 
suggesting that monocytes exposed to IL-15 have the potential to trans-present the 
cytokine to target cells expressing surface IL-15R. 
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4.4 Blocking IL­15 abrogates T­cell proliferation 
IL-15 pretreated monocytes more efficiently activate T-cell proliferation, and to 
investigate if this was a direct effect of the cytokine acting on T cells, IL-15 was 
blocked with a monoclonal neutralizing antibody prior to co-culturing monocytes with 
gluten specific TCC cells. 
 
Figure 4: Blocking IL‐15 abrogates T‐cell proliferation. A) Monocytes were pre‐treated over night with gluten and 
with or without IL‐15. Anti‐IL‐15 blocking antibody was added as depicted before co‐culturing with gluten specific 
T‐cell  clones.  B)  Percentage  of  reduced  T‐cell  proliferation  caused  by  blocking  IL‐15  relative  to  IL‐15  treated 
monocytes, showing each individual experiment displayed in (A) with the mean value. Statistics were done using 
paired t test, n=6. *≤0.05 
 
The proliferative effect of IL-15 was significantly reduced by co-culturing monocytes 
and T-cells together with anti-IL-15 blocking antibody (Figure 4). In fact, co-culturing 
with anti-IL-15 neutralizing antibody blocked almost 100% of the additional 
proliferative effect provided by IL-15 (Figure 4 B). This further suggests that IL-15 is 
either secreted or trans-presented by HLA-DQ 2+ monocytes to gluten specific TCC 
cells, and directly stimulating T-cell proliferation. 
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4.5 Monocytes do not exhibit STAT5 phosphorylation following IL­15 
stimulation 
Binding of IL-15 to IL-15R results in activation of JAK1 and JAK3 by the IL-15Rβ/γ 
complex leading to phosphorylation of STAT3 and STAT5 (1.4.5). Thus to 
investigate whether monocytes respond to IL-15, monocytes were cultured for 15 
minutes with IL-15 before fixation and intracellular staining for pSTAT5. T-cells are 
known to respond to IL-15 and IL-2 by phosphorylating STAT5 [80], and were used 
as positive controls. 
 
Figure  5:  IL‐15  and  IL‐2  induce  phosphorylation  of  STAT5  in  T  cells,  but  not  in monocytes.  T‐cell  clone(A), 
peripheral mononuclear cells (PBMCs) (B) or three different monocyte donors (C) were cultured for 15 min with 
or without IL‐15 or IL‐2 stimulation, as depicted. Gating was performed according to CD3 for PBMC T cells. 
 
Both PBMC T cells and TCCs responded to IL-15 and IL-2 by rapidly 
phosphorylating STAT5. However, monocytes appeared unresponsive to IL-15 in this 
manner (Figure 5). On the contrary, monocytes stimulated with IL-4 exhibited robust 
STAT6 phosphorylation to the same level as PBMCs (data not shown), showing that 
the monocytes are capable of responding to cytokines in vitro. This further suggest 
that the increased proliferative effect on T cells by pre-treating monocytes with IL-15,  
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is caused by surface binding of exogenous IL-15 (Figure 3) and direct presentation to 
gluten specific TCC cells (Figure 2). 
4.6 No detectable co­adjuvant effect of RA together with IL­15 
Studies have indicated that RA has co-adjuvant effects with IL-15 on APCs, 
promoting break of tolerance to dietary antigens by overriding the normally 
tolerogenic combination of RA and TGF-β[82]. To assess whether IL-15 in 
combination with RA may induce an inflammatory phenotype in monocytes, 
monocytes were pretreated with combinations of IL-15, RA, TGF-β, and gluten 
before co-culturing with gluten specific TCC cells. 
 
Figure 6: Retinoic acid  (RA) and  IL‐15 did not exhibit co‐adjuvant effects A, B) Monocytes cultured overnight 
with or without IL‐15, RA, TGF‐β and gluten, and co‐cultured with gluten specific T‐cell clones for 4 days, adding 
3H thymidine approximately 20 hours before harvesting and measuring thymidine incorporation, as depicted. B) 
Gluten pre‐treated monocytes, treated as depicted, also displayed in A). Statistics were done using paired t test, 
n=6. *≤0.05, ns=0.065. 
 
Pretreatment of monocytes with RA and TGF-β tended to reduce T-cell proliferation 
compared to unstimulated monocytes, thus indicating a tolerogenic effect of these 
factors. However, although adding IL-15 in combination with RA and TGF-β 
significantly increased proliferation compared to RA and TGF-β alone, the data did 
not reveal any co-adjuvant effects as the proliferation was not increased compared to 
IL-15 alone (Figure 5 A). On the contrary, proliferation tended to be reduced, 
although the data did not reach statistical significance. (Figure 5B)  
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4.7 IFN­γ stimulated monocytes activate T­cell proliferation in an IL­
15 dependent manner 
Monocytes have been shown to up-regulate IL-15 expression following IFN-γ 
stimulation [72], and  IFN-γ treatment effectively activate gluten specific T-cell 
proliferation [3]. Therefore, we investigated the effect of IFN-γ on monocytes ability 
to activate T-cell proliferation, and assessed whether IL-15 has a role in this system. 
To this end, we pre-treated monocytes with IFN-γ, and blocked IL-15 with a 
neutralizing antibody before co-culturing with gluten specific TCC cells.  
 
Figure 7: IFN‐γ mediated monocyte activation of T‐cell clone (TCC) cells is dependent on IL‐15. Monocytes were 
pre‐treated over night as depicted on the graph. Anti‐IL‐15 blocking antibody was added before co‐culturing with 
gluten specific T‐cell clones. Statistics were done using paired t test *≤0.05, n=6. 
 
T-cell proliferation was significantly increased after pre-treating monocytes with IFN-
γ. Strikingly, however, this effect was almost completely abrogated by blocking IL-15 
before co-culturing with gluten TCC cells (Figure 7), and was not different from that 
of untreated monocytes. This indicates that monocytes can secrete or trans-present 
endogenous IL-15 following IFN-γ stimulation, which further activates gluten specific 
T-cell proliferation.  
4.8 Transcriptional regulation of IL­15 in monocytes 
IL-15 and IFN-γ stimulated monocytes have an increased ability to induce T-cell 
proliferation, which was reduced by blocking IL-15. To further dissect the 
 
 
45
mechanism, IL-15 transcription levels in monocytes were measured by using qRT-
PCR.  
To investigate if the increased proliferative stimulation from monocytes were due to 
increased levels of IL-15 transcription following stimulation with IL-15 or IFN-γ, we 
cultured monocytes for 6, 15 and 24 hours with the different stimuli before harvesting 
and isolating RNA for further qRT-PCR analysis.  
 
 
Figure 8: Only IFN‐γ regulates IL‐15 transcription. A) Monocytes were pre‐treated over night with or without A) 
IL‐15, RA and TGF‐β, or with or without B) IFN‐γ, and harvested as depicted. *≤0.05 and **≤0.01, n=3 
 
IL-15 transcription did not appear to be regulated by pre-treating monocytes with IL-
15, RA or TGF-β (Figure 8A). However, pretreatment of monocytes with IFN-γ 
significantly up-regulated LSP-IL-15 and showed an increasing trend for SSP-IL-15 
(Figure 8B), suggesting that IL-15 is expressed by monocytes in this system. 
4.9 Increased IFN­γ­production in gluten specific T cells following 
antigen stimulation 
A hallmark for celiac disease T-cells is an increased IFN-γ production, and thus, we 
assessed if this is also true for the gluten specific tissue derived TCC cells used in this 
study. To examine the cytokine production potential to the gluten specific TCC, 
monocytes were pre-treated with combinations of IFN-γ and gluten over night before 
co-culture with TCC cells for 24 hours.  
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Figure  9:  Activated  T‐cell  clone  (TCC)  cells  produced  IFN‐γ. Monocytes were  pre‐treated  overnight with  or 
without gluten and with (A) or without (B) IFN‐γ (one representative experiment shown), before co‐culturing with 
gluten specific TCC cells. Gating was done according to  live, CD3+ T‐cells. C) Fold  induction of  IFN‐γ expression 
after pre‐treating monocytes with IFN‐γ and gluten. n=3. 
 
The data revealed that T cells co-cultured with gluten pre-treated monocytes express 
IFN-γ. Moreover, IFN-γ stimulation of monocytes further increased the number of 
IFN-γ expressing T cells (Figure 9 C). We did not, however, detect any significant 
production of IL-2 or IL-17. 
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5. Discussion and future perspectives 
IL-15 enhances the ability of HLA-DQ 2+ monocytes to activate gluten 
specific T-cell clones 
As previous showed by Beitnes et al [3], CD11c+CD14+ monocyte-derived APCs are 
increased in the small intestine of CD patients. To gain mechanistic insight into the 
antigen presentation potential of monocytes in the context of CD, monocytes were 
exposed to factors present the in celiac lesion and assessed for their ability to activate 
tissue derived gluten specific TCCs. 
Blood donors were screened for cells expressing HLA-DQ 2 (Figure 1), which is a 
prerequisite for presentation of gluten peptides to gluten specific CD4+ T-cell clones 
[3]. Monocytes from such donors were further pre-treated with factors present in the 
small intestine lamina propria of celiac disease patients to investigate their antigen 
presenting ability. Several proinflammatory-cytokines have been shown to be 
upregulated in celiac lesions, including IL-15 and IFN-γ [55], most likely acting in 
concert with constitutive intestinal factors like RA and TGF-β [84], and we wanted to 
understand the interplay between these factors. The results of the present study 
showed that monocytes pre-treated with IL-15, enhance gluten dependent T-cell 
stimulation (Figure 2). This proliferative effect on gluten specific T cells was almost 
completely abrogated by co-culturing with an anti-IL-15 antibody (Figure 4), 
suggesting that monocytes in response to IL-15 have the ability to either secrete or 
trans-present IL-15 to gluten specific T-cells, and directly induce T-cell proliferation. 
In fact, Dubois et al show that IL-15 can be trans-presented when co-expressed with 
IL-15Rα [78] acting on target cells expressing IL-15Rβ and the common γ-chain 
involved in IL-15 signaling and intracellular signal transduction [69]. In line with this, 
IL-15 shows a direct proliferative effect on the gluten specific TCCs (Figure 4), and 
monocytes were shown to have binding potential for IL-15 (Figure 3), compatible 
with the notion that IL-15 is trans-presented to gluten specific T-cells. 
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Monocytes do not respond to IL-15 by STAT5 phosphorylation 
Due to the enhanced T-cell proliferation following IL-15 monocyte stimulation 
(Figure 2), and results suggesting that IL-15 is trans-presented to T cells causing T-
cell proliferation (Figure 4), we investigated whether monocytes exhibited 
responsiveness to IL-15. STAT5 is one of the key proteins phosphorylated during IL-
15 signaling, and can therefore be used to investigate this [80].  Results of the present 
study shows that monocytes stimulated with IL-15 did not show STAT5 
phosphorylation, in contrast to T-cells used as a positive control (Figure 5).  
Monocytes stimulated with IL-4 exhibited a robust STAT6 phosphorylation (data not 
shown) as anticipated [85],  showing that monocytes are capable of responding to 
cytokines in vitro. Based on these findings it is reasonable to suggest that IL-15 has 
no stimulatory effect on freshly isolated peripheral monocytes. 
 
RA did not have a co-adjuvant effect on the HLA-DQ 2+ monocytes 
DePaolo et al has showed that RA has a co-adjuvant effect together with IL-15 on 
APCs, overriding the normally tolerogenic response of RA and TGF-β to dietary 
antigens [82].  
In the current study, pre-treating monocytes with RA, TGF-β and IL-15 did not reveal 
any additional increase in T-cell proliferation compared to IL-15 alone, thus any co-
adjuvant effect was not apparent (Figure 6). However, there are major differences 
between these two studies, e.g. their use of in vitro-generated mouse DCs instead of 
human monocytes and the induction of Foxp3+ cells as readout. In the context of 
active CD the numbers of DCs are down-regulated in the small intestine, contrary to 
newly recruited monocytes which are increased. Thus, analysis of the monocytes 
capacity to regulate T-cell stimulation appears to be more relevant to CD than 
investigating T-cell regulation by DCs [3].  
Additionally, since there are three populations of Foxp3+ cells, resting Tregs, 
activated Tregs and non-Tregs, where only two of these subpopulations are 
functionally suppressive [86, 87], the use of Foxp3+ positive cells as a readout for 
tolerogenic effects could be misleading compared with T-cell proliferation. Thus, we 
cannot directly compare these two studies, nor did the findings of the present study 
support claims that RA has an adjuvant effect together with IL-15 on APCs found in 
the gut. 
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Increased T-cell proliferation by IFN-γ stimulated monocytes depend on 
IL-15 
IFN-γ has been shown to induce IL-15 expression in monocytes [72, 78] and to 
enhance their ability to induce T-cell proliferation [3]. In accordance with this, we 
found that IFN-γ stimulated monocytes from HLA-DQ 2+ donors enhanced gluten 
specific T-cell proliferation and IFN-γ production (Figure 7 and 9). However, the 
increased T-cell proliferation was almost completely abrogated by blocking IL-15 
with a monoclonal neutralizing antibody during co-culturing of monocytes with 
gluten specific T cells. These findings suggested that IL-15 is responsible for the 
increased T-cell proliferation following IFN-γ stimulation of monocytes, and that such 
monocytes either trans-present or secrete endogenous IL-15 to T-cells. 
To further dissect the role of IL-15 during activation of gluten specific T-cell 
proliferation, we investigated how the different stimuli used in the current study 
affected transcriptional regulation of IL-15 with qRT-PCR. IL-15 transcription did not 
appear to be regulated by pre-treating monocytes with IL-15, RA or TGF-β. On the 
contrary, pre-treating monocytes with IFN-γ resulted in a significantly enhanced 
transcription of LSP-IL-15 (Figure 8), but not SSP-IL-15, although SSP-IL-15 
transcription showed a tendency to be upregulated following IFN-γ stimulation. 
Based on these findings, the source of monocyte-associated IL-15 in this system 
following pre-treatment with IL-15 or IFN-γ was most likely exogenous or 
endogenous, respectively. These findings suggests that monocyte-derived APCs in 
celiac lesions can bind exogenous IL-15 and activate gluten specific T-cell 
proliferation directly by trans-presenting the cytokine [55]. Furthermore, monocyte-
derived APCs may produce IL-15 in response to IFN-γ present in celiac lesions, 
further amplifying their T-cell stimulation capacity.  
 
Concluding remarks/summary 
Monocytes from HLA-DQ 2+ donors (Figure 1) pre-treated with gluten and IL-15 or 
IFN-γ had a significantly enhance ability to induce gluten specific T-cell proliferation 
(Figure 2 and 7). In the latter situation we also demonstrated that increased 
proliferation was paralleled by increased IFN-γ production (Figure 9). 
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Monocytes did not respond to IL-15 by exhibiting STAT5 phosphorylation (Figure 5) 
or upregulating LSP- or SSP-IL-15 (Figure 8), suggesting that IL-15 pre-treatment of 
monocytes enhance T-cell proliferation by IL-15 trans-presentation.  
Importantly, monocytes were capable of producing IL-15 following IFN-γ stimulation 
(Figure 7 and 8), and IL-15 appeared to be responsible for mediating the additive 
effect of IFN-γ on monocyte-driven T-cell proliferation. 
One can hypothesize that triggering inflammation in CD could be caused by epithelial 
stress factors, viruses, bacteria or gluten peptides, which respond by producing IL-15 
[2]. Monocyte derived APCs loaded with deaminated gluten peptides bind exogenous 
IL-15, furthermore activating gluten specific T cells initiating the initial burst of T-
cell activation, IFN-γ production and proliferation. T-cell produced IFN-γ could 
further stimulate APCs to produce and present more IL-15 to the T cells – thus 
additionally amplifying the inflammation. Monocyte derived APCs could by this 
mechanism disturb homeostatic conditions and maintain inflammation in the small 
intestine of CD patients on a gluten containing diet. 
However, IL-15 in vivo has been shown to be secreted in a heterodimer with IL-15Rα 
[88], and whether this complex can bind to IL-15Rα and be further trans-presented to 
IL-15Rβ/γ expressing cells is not known. 
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Future perspectives 
We could not detect a co-adjuvant effect of RA together with IL-15 - on the contrary, 
T-cell proliferation tended to be reduced following pre-treatment of monocytes with 
RA and IL-15. To further assess if RA can have a co-adjuvant effect on monocytes, 
investigating if monocytes express IL-15R β-chain, which is necessary for IL-15 
signaling (1.4.5), would demonstrate if they actually have the ability to directly 
respond to IL-15 or not; hence, possess the ability to respond in a co-adjuvant manner 
to IL-15 and RA. 
IL-15, in the context of celiac disease was the main focus of this study, and 
investigation of how monocytes from the small intestine lamina propria respond to IL-
15 is important. In fact, preliminary results shows that IL-15 pre-treated CD14+ cells 
isolated from small intestinal lamina propria of HLA-DQ 2+ donors, co-cultured with 
gluten specific TCC cells, enhance T-cell proliferation (data not shown). However, 
the full range of IL-15 effects on CD14+ lamina propria derived APCs should be 
assessed by T-cell proliferation assays, transcriptional analysis and analyzing the 
response to IL-15 by the presence of intracellular pSTAT5.  
Since RA has an adjuvant effect on mice DCs responding to IL-15 [82] it would be 
interesting to further explore the mechanisms behind RA on APCs from human small 
intestinal lamina propria of HLA-DQ 2+ donors, responding to IL-15.  
One approach could be assessed by performing T-cell proliferation assays, and 
investigating transcription and expression levels of IL-12p70 and IL-23, which was 
produced by RA and IL-15 stimulated mice DCs [82]. 
IL-15 is also highly expressed in intestinal autoimmune disorders referred to as 
inflammatory bowel disease (IBD) [89], which is much more complicated to manage 
then CD [90]. In addition, IL-15 has been shown to induce T-cell activation and 
proinflammatory cytokine production [89]. Therefore, treatment targeting blocking of 
IL-15 in IBD patients may be beneficial as a therapeutic agent to reduce 
inflammation. 
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